MGI Tech Achieves CE Mark Certification for DNBSEQ-T1+ Sequencer, Paving the Way for EU Market Entry

MGI Tech Achieves CE Mark Certification for DNBSEQ-T1+



In a significant development for the field of genomics, MGI Tech Co., Ltd. has officially announced that its DNBSEQ-T1+ sequencer has earned the CE Mark certification. This marks a crucial step as it enables the T1+ to enter the EU market for both research and clinical applications, thereby expanding its global footprint.

Introduced at the AGBT 2025 conference, the DNBSEQ-T1+ is touted as a flagship benchtop sequencer designed to handle mid-throughput sequencing tasks. With an impressive capability to execute a Paired-End-150 sequencing workflow with Q40 accuracy in just 24 hours, it stands out as one of the fastest sequencers in its category globally. This efficiency promises to significantly enhance various genomic research endeavors.

Versatility and Performance



The DNBSEQ-T1+ features three flow cell formats with two to four addressable lanes per flow cell, showcasing its versatility and adaptability. It supports data outputs ranging from 25 to 1,200 Gb, thereby allowing researchers to conduct independent experiments on a single platform. This adaptability is critical in improving both efficiency and operational flexibility in laboratories.

Beyond its high-performance capabilities, the T1+ is equipped with integrated automatic DNB manufacturing and loading systems along with a built-in bioinformatics module. These innovations greatly enhance user-friendliness by streamlining workflows, enabling a wide array of genomic applications while maximizing productivity in diverse research projects.

CE Mark Certification: A Testament to Quality



Duncan Yu, President of MGI, emphasized the significance of the CE Mark certification, stating, "This is a clear validation that the T1+ fully complies with the standards and regulations set forth by the EU for research and clinical use. We are confident that the availability of the T1+ holds great promise in advancing genomics and empowering researchers and clinicians in the EU to make strides in areas such as precision medicine and oncology, thanks to its precise, efficient, and versatile sequencing capabilities."

The T1+ made its debut on the European scene this year at the ESHG Conference, drawing considerable attention from attendees eager to learn about its practical applications and user experiences.

About MGI Tech



MGI Tech Co., Ltd., along with its subsidiaries — collectively known as MGI — is dedicated to advancing core instruments and technologies that drive innovations in life sciences. Established in 2016, MGI has emerged as a pioneering entity in biotechnology, focusing on the research, development, manufacturing, and distribution of instruments, reagents, and related products in the life sciences spectrum. The company excels in real-time and multi-omics systems and provides a broad range of digital devices and systems for precision medicine and various other industries.

Today, MGI operates globally, servicing clients across six continents with dedicated research, production, training, and customer service facilities. MGI has become one of the select few companies capable of independently developing clinical-grade gene sequencers with varying throughput capacities, exemplifying its commitment to impactful contributions in the science community.

For more information about MGI, visit their website at MGI Tech, LinkedIn, X, and YouTube.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.